Grifols (Grifols) Accounts Payable & Accrued Expense

: $0 Mil (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

Grifols's quarterly accounts payable & accrued expense declined from Dec. 2022 ($1,129 Mil) to Jun. 2023 ($0 Mil) but then stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil).

Grifols's annual accounts payable & accrued expense increased from Dec. 2021 ($1,086 Mil) to Dec. 2022 ($1,129 Mil) and increased from Dec. 2022 ($1,129 Mil) to Dec. 2023 ($1,276 Mil).

Grifols Accounts Payable & Accrued Expense Historical Data

The historical data trend for Grifols's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

1,032.67

1,057.43

1,085.96

1,129.23

1,276.05

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense																-	1,129.23	-	-	1,276.05

Grifols Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.